Athena, Elan deal

The companies will apply ELN's drug delivery technologies to certain neurological products developed by ATHN (South San Francisco). The companies declined to specify the individual products but said that a development agreement has been executed for the first product in the area of Parkinson's disease.

ELN will provide pharmaceutical development and manufacture products. ATHN will assume responsibility for clinical development, regulatory submissions, marketing and distribution in its territories. ATHN will retain exclusive marketing and distribution rights in the U.S., Canada and Mexico, and will share those rights with ELN in the U.K. ELN retains all rights for collaborative products elsewhere. ...